FDA and FTC warned UPSY LLC that its website sells CBD products claimed to treat or prevent COVID-19 as unapproved, misbranded drugs.
What happened
FDA reviewed the company's website, www.upsy.com, on February 17, 2022, and the FTC reviewed it on March 15, 2022. The site offered cannabidiol (CBD) products for sale with blog posts saying CBD "may help patients cope with symptoms" of COVID-19, is "a potent anti-inflammatory" in the fight against COVID, and "can mitigate ARDS-like symptoms." No inspection was conducted; the findings come from the website review.
What FDA found
The company sells CBD products as treatments for COVID-19 without FDA approval, which makes them unapproved new drugs.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The products are misbranded because their labeling makes claims the drug has not been approved for.
Section 502 of the FD&C Act, 21 U.S.C. § 352Shipping these products across state lines is prohibited.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertises that its products prevent, treat or cure disease without competent and reliable scientific evidence, which the FTC Act forbids.
FTC Act, 15 U.S.C. § 41 et seq.Deceptive claims about treating, curing, preventing or mitigating COVID-19 can bring civil penalties of up to $46,517 per violation.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260The company must stop making unsubstantiated COVID-19 claims and may have to refund consumers.
Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b)
What FDA wants
FDA tells the company to immediately stop selling unapproved products claimed to prevent or treat COVID-19, and within 48 hours to email COVID-19-Task-Force-CDER@fda.hhs.gov describing the steps taken and how it will prevent repeat violations. The FTC separately requires a certification within 48 hours that the unsubstantiated claims have stopped.
Who should pay attention
- CBD and supplement brands that make health claims on their websites
- e-commerce sellers of CBD and wellness products
- marketing and regulatory reviewers who approve online product content
This is a summary. Read the original letter on fda.gov.